CMO Dr. Andrew Hertler on the Recent FDA ODAC Meeting
New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncol...
Our chief medical officer highlights noteworthy research and results from clinical oncology's premier event.
New Century Health, a national leader in specialty care management, is proud to provide comprehensive oncology specialty management services to Neighborhood Health Plan of Rhode Island.
Our CMO Dr. Andrew Hertler speaks with HFMA about the role of telehealth in oncology care today.
Senior Medical Director Fernando Villacian lays out the key tenets of an effective cardiovascular management program.
Our senior medical director speaks with Journal of Clinical Pathways about preventing inappropriate use in cardiology.
New Century Health announced that 2020 was the largest membership growth year in the 19-year history of the company.
A new research effort aims to gauge whether certain groups of patients receive high-value therapies at lower rates than others.
Payer strains now top the list of stressors facing oncologists, with prior authorization as the most-cited source of that payer stress.
Evolent Health, Parent Company of New Century Health, Names Kim Keck to Board of Directors. Announces Cheryl Scott to Serve as Lead Independent Director.
NCH's approach to more appropriate use of myeloid growth factor provides a playbook for how to change prescribing patterns.
New Century Health recently convened health plan executives, industry experts and oncologists from across the nation to discuss the confluence of forces shaping oncology care in 2021 and beyond.
The company will leverage New Century Health’s oncology specialty management program to help ensure its more than 125,000 Medicare Advantage members receive high-quality cancer care.
New Century Health's John Davis recently sat down with Dr. Prasad, author of "Malignant: How Bad Policy and Bad Evidence Harm People with Cancer," to discuss key forces impacting cancer care.
Our CMO Dr. Andrew Hertler explains how real world evidence may usher in the next generation of clinical oncology pathways.
Recent journal article details how NCH and Cancer Care Specialists of Illinois teamed up to slow growth in drug spend.
NCH also recertified by HITRUST® for patient privacy and data security protection.
Specialty care management company also recertified by HITRUST® for patient privacy and data security protection.
Dr. Mark Walshauser describes the impact of high-value oncology pathways and peer collaboration on his community practice.
Increasing use of real-world evidence is one of the most exciting trends in pathway development, our CMO tells Journal of Clinical Pathways.